MB
GERN icon

MPM BioImpact’s Geron GERN Stock Holding History

MPM BioImpact’s Portfolio GERN Stock Details GERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,475,675
Closed -$34.6M – 46
2024
Q1 		$34.6M Sell
10,475,675
-239,945
-2% -$538K 5.56% 2
2023
Q4 		$22.6M Buy
10,715,620
+3,139
+0% +$6.1K 5.29% 4
2023
Q3 		$22.7M Buy
10,712,481
+1,521,191
+17% +$4.13M 6.06% 3
2023
Q2 		$29.5M Buy
9,191,290
+789,725
+9% +$2.25M 5.94% 4
2023
Q1 		$18.2M Sell
8,401,565
-65,416
-0.8% -$186K 4.74% 8
2022
Q4 		$20.5M Buy
8,466,981
+44,399
+0.5% +$99.5K 5.32% 7
2022
Q3 		$19.7M Sell
8,422,582
-12,409
-0.1% -$27.8K 4.67% 7
2022
Q2 		$13.1M Buy
8,434,991
+2,285,714
+37% +$3.23M 3.63% 7
2022
Q1 		$8.36M Buy
6,149,277
+525,388
+9% +$586K 2.24% 11
2021
Q4 		$6.86M Sell
5,623,889
-108,881
-2% -$156K 1.25% 20
2021
Q3 		$7.85M Buy
+5,732,770
New +$7.65M 1.22% 19

Other funds holding GERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

MPM BioImpact's GERN Position: Q2 2024 in Review

MPM BioImpact sold out of Geron (GERN) in Q2 2024, closing a stake of 10,475,675 shares — an estimated $34.6M sold.

MPM BioImpact first reported a position in GERN in Q3 2021 and held it in 11 quarters. The position peaked at $34.6M in Q1 2024. 239 funds tracked by Wall St. Rank hold GERN as of Q2 2024.

  • MPM BioImpact reported no remaining Geron position as of Q2 2024 after selling out during the quarter.
  • MPM BioImpact sold 10,475,675 Geron shares in Q2 2024, an estimated $34.6M.
  • MPM BioImpact first reported a position in Geron in Q3 2021 and held it in 11 quarters.
  • MPM BioImpact's Geron position peaked at $34.6M in Q1 2024.
  • 239 funds tracked by Wall St. Rank held Geron as of Q2 2024.

Based on MPM BioImpact's 13F filing for Q2 2024, filed 14 Aug 2024.